Evidence map›Paper›PMID 32104010›Full record

ArticleInfection and drug resistance2020

Antifungal Activity of ZnO Nanoparticles and Nystatin and Downregulation of SAP1-3 Genes Expression in Fluconazole-Resistant

Seyededeh Sedigheh Hosseini, Hamidreza Joshaghani, Tahereh Shokohi, Alireza Ahmadi, Zahra Mehrbakhsh

Open access · goldAbstract read
In one paragraph

Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Zinc oxide nanoparticles againstFrontiers in antibiotics · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Mechanisms of Antifungal Properties of Metal Nanoparticles.Nanomaterials (Basel, Switzerland) · 2022
    Review
  13. Green Synthesis of Zn(OH)Nanomaterials (Basel, Switzerland) · 2022
    Article
  14. Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Seyededeh Sedigheh HosseiniLaboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.ORCID 0000-0002-6250-6416
Hamidreza JoshaghaniDepartment of Clinical Biochemistry, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Tahereh ShokohiDepartment of Medical Mycology and Parasitology, Mazandaran University of Medical Sciences, Sari, Iran.
Alireza AhmadiLaboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Zahra MehrbakhshDepartment of Biostatistics and Epidemiology, School of Health, Golestan University of Medical Sciences, Gorgan, Iran.
Golestan University · IRMazandaran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAntifungal resistance and virulence properties of PATIENTS AND

methodsIn this descriptive-analytic study, vaginal samples were collected from 280 VVC women. 196 (70%) of

resultsIt was revealed that PCR amplified the ERG11 gene in all of the Fluconazole-resistant isolates. Real-time PCR was used to survey the effects of 3±1.7µg/mL concentrations of ZnO nanoparticles and Nystatin on expression of SAP1-3 genes before and after treatment. 186 (95%) susceptible

conclusionZnO as antifungal agent can well reduce the growth and gene expression of SAP1-3 in the pathogenesis of VVC.

Indexed as

gene expressionpathogenesisvulvovaginal candidiasisZnO

Identifiers

PMID32104010
PMCPMC7025901
OpenAlexW3006258102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.